Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial
- PMID: 24432995
- DOI: 10.1210/jc.2013-3276
Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial
Abstract
Context: Living in a prediabetes state significantly increases a patient's risk for both diabetes and cardiovascular disease. Tianqi capsule, containing 10 Chinese herbal medicines, is used in China for the treatment of type 2 diabetes mellitus (T2DM).
Objective: The purpose of this study was to assess whether Tianqi prevented T2DM in subjects with impaired glucose tolerance (IGT) over the course of a 12-month treatment.
Methods: Individuals with IGT were randomly allocated in a double-blind manner to receive Tianqi (n = 210) or a placebo (n = 210) for 12 months. Oral glucose tolerance tests were conducted every 3 months to assess the development of diabetes or restoration to normal glucose tolerance. All subjects received the same lifestyle education. The primary endpoint was the conversion of IGT to T2DM. Body weight and body mass index were observed. Adverse effects were monitored.
Results: Of the 420 enrolled subjects with IGT, 389 completed the trial (198 in the Tianqi group and 191 in the placebo group). At the end of the 12-month trial, 36 subjects in the Tianqi group (18.18%) and 56 in the placebo group (29.32%) had developed diabetes (P = .01). There was a significant difference in the number of subjects who had normal glucose tolerance at the end of the study between the Tianqi and placebo groups (n = 125, 63.13%, and n = 89, 46.60%, respectively; P = .001). Cox's proportional hazards model analysis showed that Tianqi reduced the risk of diabetes by 32.1% compared with the placebo. No severe adverse events occurred in the trial. There were no statistical differences in body weight and body mass index changes between the Tianqi group and the placebo group during the 12-month trial.
Conclusions: Treatment with a Tianqi capsule for 12 months significantly decreased the incidence of T2DM in subjects with IGT, and this herbal drug was safe to use.
Similar articles
-
The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.Trials. 2015 Nov 3;16:496. doi: 10.1186/s13063-015-0990-9. Trials. 2015. PMID: 26530718 Free PMC article. Clinical Trial.
-
A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.Exp Clin Endocrinol Diabetes. 2008 May;116(5):282-8. doi: 10.1055/s-2007-1022521. Exp Clin Endocrinol Diabetes. 2008. PMID: 18484560 Clinical Trial.
-
Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.J Clin Endocrinol Metab. 2013 Dec;98(12):4691-701. doi: 10.1210/jc.2012-4096. Epub 2013 Sep 20. J Clin Endocrinol Metab. 2013. PMID: 24057294 Clinical Trial.
-
Prevention of Type 2 Diabetes with the Chinese Herbal Medicine Tianqi Capsule: A Systematic Review and Meta-Analysis.Diabetes Ther. 2017 Dec;8(6):1227-1242. doi: 10.1007/s13300-017-0316-x. Epub 2017 Oct 13. Diabetes Ther. 2017. PMID: 29027648 Free PMC article. Review.
-
Preservation of β-cell function: the key to diabetes prevention.J Clin Endocrinol Metab. 2011 Aug;96(8):2354-66. doi: 10.1210/jc.2011-0246. Epub 2011 Jun 22. J Clin Endocrinol Metab. 2011. PMID: 21697254 Review.
Cited by
-
Effect of Gegen Qinlian Decoction on the regulation of gut microbiota and metabolites in type II diabetic rats.Front Microbiol. 2024 Aug 21;15:1429360. doi: 10.3389/fmicb.2024.1429360. eCollection 2024. Front Microbiol. 2024. PMID: 39234553 Free PMC article.
-
Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy.Pharm Biol. 2024 Dec;62(1):592-606. doi: 10.1080/13880209.2024.2374794. Epub 2024 Jul 19. Pharm Biol. 2024. PMID: 39028269 Free PMC article. Review.
-
A comprehensive in-vitro/in-vivo screening toolbox for the elucidation of glucose homeostasis modulating properties of plant extracts (from roots) and its bioactives.Front Pharmacol. 2024 Jun 26;15:1396292. doi: 10.3389/fphar.2024.1396292. eCollection 2024. Front Pharmacol. 2024. PMID: 38989154 Free PMC article. Review.
-
Editorial: Clinical evidence for and advances in translational research on the classic formulas of traditional Chinese medicine.Front Pharmacol. 2024 Apr 15;15:1392930. doi: 10.3389/fphar.2024.1392930. eCollection 2024. Front Pharmacol. 2024. PMID: 38686321 Free PMC article. No abstract available.
-
Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application.Front Pharmacol. 2024 Mar 6;15:1339148. doi: 10.3389/fphar.2024.1339148. eCollection 2024. Front Pharmacol. 2024. PMID: 38510656 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
